CX3CL1 and rheumatoid arthritis: Indeed, contradicting our current results, a decline in CX3CL1 plasma levels has been seen in RA patients as a response to treatment with TNF inhibitors or a biologic drug abatacept, a fusion protein preventing T cell activation [32, 33].